SCHEMBL21403972

SCHEMBL21403972

O=C1NC(=O)C(CCC(=O)N2CCC(c3ccc(F)c(F)c3)CC2)N1

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 16/20 0.67
▸ ADAM17 P78536 6/20 0.67
▸ ADAMTS4 O75173 2/20 0.56
▸ ADAM10 O14672 1/20 0.56
▸ MMP12 P39900 1/20 0.56
▸ ADAM9 Q13443 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19691629 1.00 ADAMTS5 (0.67) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL21403976 0.91 ADAMTS5 (0.69) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL19692463 0.91 ADAMTS5 (0.69) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL21403980 0.88 ADAM17 (0.81) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL19692239 0.88 ADAM17 (0.81) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL19701803 0.83 ADAMTS5 (0.69) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL19691588 0.83 ADAMTS5 (0.69) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL21403966 0.82 ADAM17 (0.91) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL19692490 0.82 ADAM17 (0.91) ADAMTS5ADAM17ADAMTS4ADAM10MMP12
SCHEMBL20708577 0.82 ADAMTS5 (0.78) ADAMTS5ADAM17ADAMTS4ADAM10MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468961-B1 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2020-06-10 — — EP claimed
US-10550100-B2 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis GALAPAGOS NV (BE) 2020-02-04 — — US claimed
US-20190300503-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-03 — — US claimed
EP-3468961-B1 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2020-06-10 — — EP disclosed
EP-3468961-B1 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2020-06-10 — — EP disclosed
US-10550100-B2 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis GALAPAGOS NV (BE) 2020-02-04 — — US disclosed
US-20190300503-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300503-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS ADAMTS5, ADAMTS4, ADAMTS1 ADAMTS5 1/4885ADAM17 10/4885ADAMTS4 2/4885
US-10550100-B2 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis ADAMTS5, ADAMTS4, ADAMTS1 ADAMTS5 1/4885ADAM17 8/4885ADAMTS4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback